Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + XELOX + Bevacizumab in 1st Line RAS-Mutant Metastatic Colorectal Cancer
NCT05171660Phase 3Active, not recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sintilimab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression Free Survival up to 2 years. Started Feb 2022; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05171660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171660.